findmyKOL

Manuel Chavarri, MD

Basic profile

Endocrinology, Diabetes & Metabolism

ORCIDNone on fileNPI
RegionAlpena, MI · MidwestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2023findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication1993Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Manuel Chavarri is an Endocrinology/Metabolic physician. OpenAlex indexes 9 publications with 215 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
9publications

Distinct works indexed by OpenAlex.

215citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

346 Long Rapids Plz
Alpena, MI 497071374

Telephone

989-358-3500

Provider last certified this registry record 22 Feb 2021.

View the NPPES registry record

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    33.1%
    Insulin Analog10.1%
    Lantus Solostar36%Tresiba Flextouch U-10012%Humalog Kwikpen U-1009%Novolog Flexpen9%Novolog5%Basaglar Kwikpen U-1004%Lantus4%Fiasp Flextouch4%Tresiba Flextouch U-2003%Toujeo Max Solostar3%Toujeo Solostar3%Humalog3%Soliqua 100-333%
    Part D<11 patients
    Biguanide (metformin)6.8%
    Metformin Hcl Er59%Metformin Hcl41%
    Part D50 patients

    + 10 more classes in this area

  • Cardiovascular

    32.8%
    Statin10.2%
    Rosuvastatin Calcium37%Atorvastatin Calcium35%Simvastatin14%Pravastatin Sodium11%Lovastatin4%
    Part D<11 patients
    Beta blocker5.3%
    Metoprolol Succinate36%Atenolol24%Metoprolol Tartrate15%Carvedilol10%Propranolol Hcl7%Acebutolol Hcl5%Propranolol Hcl Er5%
    Part D<11 patients

    + 12 more classes in this area

  • Hormonal (systemic)

    16.2%
    l-Thyroxine12.1%
    Levothyroxine Sodium92%Synthroid8%
    Part D157 patients
    Antihypoglycemic Agent1.6%
    Gvoke Hypopen 2-Pack76%Gvoke Hypopen 1-Pack24%
    Part D32 patients

    + 6 more classes in this area

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”